Suggested remit: To appraise the clinical and cost effectiveness of nivolumab within its marketing authorisation for the adjuvant treatment of muscle-invasive urothelial cancer with high-risk of recurrence following surgical resection.
Status In progress
Process STA 2018
ID number 2694

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
01 October 2020 - 29 October 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
31 July 2019 In progress. DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance